Filing Flows

Filing Flows › 10x Genomics (TXG) › Next earnings date

10x Genomics (TXG) earnings: beat the estimate

10x Genomics (TXG) reported on Nov 5, 2026 and beat the EPS estimate: $0.03 against −$0.02 (+240.3%). Revenue was $151M for Q3 2026, +1% year over year. It beat the EPS estimate in 100% of the quarters on record.

Last result+240.3% vs estimate
Beat rate100%

The last report

10x Genomics reported revenue of $151M for the third quarter 2026 (+1% Y/Y), net loss $19.4M: Consumables $134M, Services $9.0M, Instruments $6.9M. How it makes money → · Every quarter →

10x Genomics: EPS against the estimate, last 5 reports10x Genomics: EPS against the estimate, last 5 reportsEstimateReported−$0.07−$0.02Nov 25−$0.04$0.07Feb 26−$0.06$0.07May 26−$0.02$0.03Aug 26−$0.02$0.03Nov 26
Latest (Nov 26): Estimate −$0.02, Reported $0.03.

10x Genomics' latest quarter

10x Genomics, Q3 2026: revenue $151M (+1% year over year), operating margin -10.7%, net loss $19.4M, operating cash flow $15.8M. The chart follows the revenue to costs, profit and cash.

Questions

Did 10x Genomics beat earnings?

10x Genomics (TXG) reported on Nov 5, 2026 and beat the EPS estimate: $0.03 against −$0.02 (+240.3%).

When does TXG report earnings?

The next date is not set yet.

Does 10x Genomics usually beat earnings?

It beat the consensus EPS estimate in 100% of the quarters on record.

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.